The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in ...

Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking ...

The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

Lilly to Develop Two Targets Identified and Validated Using ’ AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of ...

The new mens range debuted at a VIP fashion show in Palm Beach last week, and will arrive in stores in February for the ...

Lilly and Pfizer stocks have sold off sharply in recent weeks. Both drugmakers have had some bad news that caused their stock ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...